58 results about "FGF21" patented technology

The peptide complex of the present invention promotes the expression of the SIRT1 gene, referred to as a longevity gene, promotes the expression of the FGF21 gene, and increases the phosphorylation of AMPK. In addition, the peptide complex of the present invention exhibits an anti-inflammatory effect. Therefore, the peptide complex of the present invention inhibits aging, promotes the expression of the longevity gene SIRT1 gene, and can be used for treating or preventing diseases associated with SIRT1.

Provided are a GLP-1GIP analog, an FGF21 protein, a trifunctional protein, and use thereof. The trifunctional protein comprises the GLP-1 / GIP analog and the FGF21 protein. Further provided is use of the GLP-1 / GIP analog, the FGF21 protein, and the trifunctional protein in the preparation of a drug for preventing and / or treating diseases related to GLP-1, GIP, and / or FGF21. The provided GLP-1 / GIP analog, FGF21 protein, and trifunctional protein can synergistically regulate blood glucose and lipid levels in vivo, meet multiple needs in patients with type 2 diabetes, including lowering blood glucose, alleviating hepatic steatosis, promoting weight loss, ameliorating circulating lipid metabolism disorder, etc., and have better biological safety and tolerability and longer in vivo half-lives.

The invention discloses a GLP-1 GIP analogue, an FGF21 protein, a three-function protein and an application thereof. The trifunctional protein comprises a GLP-1 / GIP analogue and an FGF21 (Fibroblast Growth Factor 21) protein. The invention also discloses application of the GLP-1 / GIP analogue, the FGF21 protein and the three-function protein in preparation of medicines for preventing and / or treating diseases related to GLP-1, GIP and / or FGF21. The GLP-1 / GIP analogue, the FGF21 protein and the three-function protein provided by the invention can synergistically regulate blood sugar and lipid levels in vivo, meet multiple requirements of patients with type 2 diabetes for reducing blood sugar, relieving liver fatty degeneration, reducing weight, improving circulating lipid metabolism disorder and the like, and are better in biological safety and tolerance and longer in in-vivo half-life period.

According to various aspects of this disclosure, the present disclosure relates to methods for reducing kidney inflammation, reducing kidney fibrosis, reducing oxidative stress in the kidney, preventing or reducing the likelihood of chronic kidney disease (CKD), treating or preventing acute kidney injury (AKI) or treating a kidney disease in a subject in need thereof comprising administering, e.g., intramuscularly, to the subject a recombinant adeno-associated virus (rAAV) vector, wherein the rAAV vector comprises a vector genome comprising a nucleotide sequence encoding a Fibroblast growth factor 21 (FGF21) or a functional fragment thereof and an AAV capsid (e.g., AAV1 serotype), optionally, wherein the subject does not suffer from diabetes.

The invention relates to the identification of fusion proteins comprising polypeptide and protein variants of fibroblast growth factor 21 (FGF21) with improved pharmaceutical properties. Also disclosed are methods for treating FGF21-associated disorders, including metabolic conditions.

This invention relates to the field of cosmetics, and more particularly to active oligopeptides and their application in the preparation of anti-aging products. This invention provides an active oligopeptide with anti-aging activity, the amino acid sequence of which is shown in SEQ ID NO:1 and / or SEQ ID NO:4. This invention also provides an active oligopeptide (β1 and β1c) designed based on computational structural biology, targeting the β-Klotho FGF19 / / FGF21 and receptor-binding arm (RBA) region, and optimized for physicochemical properties, for use in skin anti-aging.

This disclosure generally relates to methods and compositions for functional genetic modifications at selected genomic sites, such as the FGF21 gene or the GDF15 gene. This disclosure further provides compositions and methods for genomic editing of AU-rich elements in the FGF21 and / or GDF15 genes for treating obesity-related diseases and disorders.

Provided herein are polynucleotides comprising a coding sequence for expression of a fibroblast growth factor 21 (FGF21) pathway activating agent. Also provided are vectors, recombinant viral genomes, and recombinant virus compositions comprising said polynucleotides, as well as associated methods.

A long-acting FGF21 derivative, specifically relating to an FGF21 derivative comprising an FGF21 mutant protein and a fatty acid chain. The FGF21 derivative, which is obtained by coupling the fatty acid chain to a cysteine residue at position 172 of an FGF21 protein by means of a linker, has relatively high FGF21 activity, and has a better weight loss effect in model mice. The FGF21 mutant protein not only retains the activity of mature FGF21, but also has significantly improved stability in serum.

Provided is a fusion protein, which binds to ACTRII, also can activate a GLP1 receptor and / or an FGF21 receptor, and has better muscle-building and fat-reducing effects in a weight-reducing use.

The application discloses preparation of a canine fibroblast growth factor 21 fusion protein and application thereof in treating atopic dermatitis. The application provides a caninized fibroblast growth factor 21 (FGF21) fusion protein, which is composed of a caninized fibroblast growth factor 21 (FGF21) and a fusion tag, and the fusion tag is TAT or R11 or Fc. The three kinds of FGF-21 fusion proteins obtained by the application can effectively improve the symptoms of atopic dermatitis of mice and reduce the expression level of related inflammatory factors. The three kinds of FGF-21 recombinant fusion proteins provided by the application can be used as potential drugs for treating atopic dermatitis of dogs.

To provide a gene construct for use in the treatment of a metabolic disorder in a mammal, particularly a human.SOLUTION: A gene construct provided comprising a nucleotide sequence encoding fibroblast growth factor 21 (FGF21) for use in the treatment and / or prevention of a metabolic disorder, wherein the therapy involves expression of the gene construct in the central nervous system (CNS), preferably in the brain, more preferably in the hypothalamus and / or cortex and / or hippocampus and / or cerebellum and / or olfactory bulb, and most preferably in the hypothalamus.SELECTED DRAWING: None

The application provides a curcumin composition-FGF21 functional protein co-assembly microparticle applied to liver diseases and a preparation method thereof, and comprises the following steps: extracting turmeric by dynamic warm soaking, obtaining turmeric filtrate after centrifugation, concentration and microfiltration; preparing high-purity curcumin composition through PS-NVP specific purification and 80% ethanol gradient elution; and preparing Curs-FGF21 co-assembly microparticles through oil-water phase assembly and centrifugation by taking a polymer as a carrier, compounding the curcumin composition with FGF21 protein. The microparticle can improve drug stability and bioavailability, realizes long-acting slow release, can regulate liver cell lipid metabolism, reduce liver lipid accumulation and inflammation, significantly improves liver damage and liver fibrosis, and has outstanding liver protection and repair effects. The process is stable and controllable, has outstanding innovation, and provides a brand-new candidate preparation research and development idea and technical scheme for the prevention and treatment of metabolic liver diseases.

Peptides consisting of the amino acid sequence of any of LIVTQTMKGL (SEQ ID NO: 1), LIVTQTMKG (SEQ ID NO: 2), LIVTQTMK (SEQ ID NO: 3), IVTQTMKGL (SEQ ID NO: 4), IVTQTMKG (SEQ ID NO: 5), and VTQTMKGL (SEQ ID NO: 6) are useful for improving intestinal barrier function, for suppressing blood glucose elevation, for improving insulin sensitivity, for promoting FGF21 secretion, for suppressing stress or protecting nerves, or for reducing fatigue.

The present invention relates to fusion proteins comprising a GLP-1R (glucagon-like peptide-1 receptor) agonist and an FGF21 (fibroblast growth factor 21) compound, which are useful for the treatment of diabetes, obesity and other disorders of abnormal glycolipid metabolism.

The present invention relates to combinations, pharmaceutical compositions and fusion molecules comprising an FGF21 (fibroblast growth factor 21) compound and a GLP-1R (glucagon-like peptide-1 receptor) agonist, with an optimized GLP-1R agonist / FGF21 compound activity ratio. The present invention also relates to the use of said combinations, pharmaceutical compositions and fusion molecules as medicaments, in particular for the treatment of obesity, overweight, metabolic syndrome, diabetes, diabetic retinopathy, hyperglycemia, dyslipidemia, non-alcoholic steatohepatitis (NASH) and / or atherosclerosis.

The application discloses a mesenchymal stem cell preparation expressing FOXO3 and FGF21 and application thereof, relates to biological medicine, and a parent plasmid carrying a therapeutic gene of the mesenchymal stem cell expressing FOXO3 and FGF21 has a nucleotide sequence as shown in SEQ ID No: 01; the application provides a mesenchymal stem cell preparation capable of simultaneously expressing FOXO3 and FGF21, which can effectively improve insulin glucose tolerance, effectively reduce the content of glycosylated hemoglobin, and has the potential to treat human type 2 diabetes.

The present invention relates to extracellular vesicles having FGF21 linked to the surface thereof, and use thereof. The extracellular vesicles according to one embodiment can alleviate steatosis, reduce inflammation and fibrosis, and alleviate a decrease in bone density, which is a side effect occurring when FGF21 is used alone, and thus can be effectively used for preventing and treating liver diseases including metabolic abnormality-related steatohepatitis.

The present invention provides fusion proteins comprising a fibroblast growth factor 1 (FGF1) peptide and a fibroblast growth factor 21 (FGF21) peptide. Pharmaceutical compositions and wound dressings comprising the fusion proteins, polynucleotides encoding the fusion proteins, and methods of using the fusion proteins to treat a condition in a subject are also provided.

Provided herein arc polynucleotides comprising a coding sequence for expression of a fibroblast growth factor 21 (FGF21) pathway activating agent. Also provided are vectors, recombinant viral genomes, and recombinant virus compositions comprising said polynucleotides, as well as associated methods.

The present application discloses the use of FGF21 / GLP-1 fusion proteins in the preparation of a medicament for preventing and / or treating at least one of type 2 diabetes, obesity, steatohepatitis, and triglyceridemia. The FGF21 / GLP-1 fusion proteins of the present application are effective in treating at least one of type 2 diabetes, obesity, steatohepatitis, and triglyceridemia, and in particular, can reduce at least one of HbA1c, blood glucose, body weight, liver fat content, ALT, AST, glutamyl transpeptidase, triglyceride, total cholesterol, low-density lipoprotein cholesterol, or increase at least one of adiponectin, insulin sensitivity, and beta-cell function in the subject.

The invention relates to a long-acting fibroblast growth factor 21 fusion protein and application thereof. The amino acid sequence of the fusion protein is shown as SEQ ID No.1, the half-life period of the fibroblast growth factor 21 can be effectively prolonged, then the fibroblast growth factor 21 has the long-term effect, and on the basis, the fusion protein retains the known functions of the fibroblast growth factor 21. In addition, the invention also finds that the fusion protein Nb-FGF21 can significantly improve the skin stains, so that the skin stains can be treated based on the fusion protein Nb-FGF21.

A fusion protein and a use thereof. The fusion protein comprises an FGF21 mutant protein. The FGF21 mutant protein comprises modifications based on a wild-type human FGF21 sequence, the modifications being: deletion of a proline residue at position 171, or formation of a pair of disulfide bonds before and after the proline residue at position 171 by means of substitution, deletion, or addition of one or more amino acid residues. The FGF21 mutant protein is resistant to enzymatic degradation at the C-terminus thereof by a fibroblast activation protein (FAP), maintains C-terminus activity for binding to a β-klotho receptor, thereby extending an in vivo half-life and the pharmacological effect. The fusion protein enhances the therapeutic efficacy thereof in weight loss, blood glucose reduction, and non-alcoholic steatohepatitis (NASH) by fusing the FGF21 mutant protein with other molecules, such as GLP-1.

According to various aspects of this disclosure, the present disclosure relates to a method for treating or reducing pulmonary inflammation and / or pulmonary fibrosis in a subject in need thereof comprising intramuscularly administering to the subject a recombinant adeno-associated virus (rAAV) vector. In some aspects, the rAAV vector comprises a vector genome and an AAV capsid (e.g., an AAV1 serotype). In some aspects, the vector genome comprises AAV inverted terminal repeats (ITRs) flanking an expression construct comprising a nucleotide sequence encoding a Fibroblast growth factor 21 (FGF21) or functional fragment thereof operably linked to a ubiquitous promoter.

To provide fusion proteins with optimized GLP-1R agonist / FGF21 compound activity ratio.SOLUTION: The invention relates to a fusion protein comprising a glucagon-like peptide 1 receptor 5 (GLP-1R) agonistic peptide and a variant of human fibroblast growth factor 21 (FGF21). The invention further relates, in particular to the use of a fusion protein comprising a GLP-1R agonistic peptide and a variant of FGF21 as a medicament for treating obesity, overweight, metabolic syndrome, diabetes, diabetic retinopathy, hyper glycemia, dyslipidemia, non-alcoholic steatohepatitis (NASH) and / or atherosclerosis in a subject. The invention further relates to pharmaceutical compositions comprising a fusion protein comprising a GLP-1R agonistic peptide and a variant of FGF21.SELECTED DRAWING: None

Provided in the present invention are a fatty-acid-chain-modified GLP-1-FGF21 fusion protein, and a preparation method therefor and the use thereof. In the fusion protein, after a specific mutation site is introduced at the C-terminus of FGF21, the terminus of GLP-1-FGF21 is subjected to a fatty-acid-chain modification by using a Sortase-A enzyme-mediated molecular modification technique. The fatty-acid-chain modification can achieve: extended half-life of GLP-1-FGF21; slowed terminal degradation of FGF21 by fibroblast activation protease (FAP); and low-cost operation and rapid preparation of the GLP-1-FGF21 fusion protein in an aqueous solution at room temperature. The enzyme-mediated molecular modification technique is used on the GLP-1-FGF21 fusion protein of the present invention, thereby providing significant advantages.

This invention discloses the preparation of canine fibroblast growth factor 21 fusion proteins and their use in the treatment of atopic dermatitis. This invention provides canine fibroblast growth factor 21 (FGF21) fusion proteins, which are composed of canine fibroblast growth factor 21 (FGF21) and a fusion tag, which may be TAT, R11, or Fc. The three FGF-21 fusion proteins obtained by this invention can effectively improve the symptoms of atopic dermatitis in mice and reduce the expression levels of related inflammatory factors. The three recombinant FGF-21 fusion proteins provided by this invention can serve as potential drugs for the treatment of canine atopic dermatitis.

The invention relates to a viral expression construct and related viral vector and nucleic acid molecule and composition and to their use wherein said construct and vector are suitable for expression in a mammal and comprise a nucleotide sequence encoding a Fibroblast growth factor 21 (FGF21) to be expressed in liver, adipose tissue and / or skeletal muscle.

Provided are a modified mesenchymal stem cell and culture supernatant thereof, and a pharmaceutical composition comprising said cell or culture supernatant thereof. The mesenchymal stem cell is capable of expressing: (1) a first protein, which is selected from FGF21 or a variant thereof, or a first fusion protein comprising the FGF21 or the variant thereof; and (2) a second protein, which is selected from GLP-1 or a variant thereof or a second fusion protein comprising the GLP-1 or the variant thereof. Also provided is the use of the modified mesenchymal stem cell and culture supernatant thereof, and the pharmaceutical composition comprising said cell or culture supernatant thereof in the treatment of metabolic diseases and in the preparation of a medicament for treating metabolic diseases.

GLP-1-Fc-FGF21 double-target fusion protein composition and its use. The composition comprises a GLP-1-Fc-FGF21 fusion protein and a buffer solution. In the composition, by adding the buffer solution, the formation of visible particles can be effectively controlled, the stability of the GLP-1-Fc-FGF21 fusion protein can be improved, and the shelf life of the product can be extended. The composition can be used to treat and / or prevent metabolic diseases such as diabetes, dyslipidemia, obesity, and diseases associated with fatty liver.